View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
April 16, 2020updated 12 Jul 2022 11:55am

Disrupted clinical trials due to Covid-19

In a recent GlobalData poll that was completed by readers of Cinical Trials Arena between March 26 and April 2, it was found that 52% of the 527 respondents think it is very likely that there will be clinical trial delays as a result of the coronavirus outbreak.

By GlobalData Healthcare

In a recent GlobalData poll that was completed by readers of Cinical Trials Arena between March 26 and April 2, it was found that 52% of the 527 respondents think it is very likely that there will be clinical trial delays as a result of the coronavirus outbreak. Since early March, upwards of a hundred companies have publically announced disruptions to planned and ongoing clinical trials in their press releases, SEC filings, as well as on social media. Companies have delayed the initiation of planned trials or withdrawn these completely, as well as suspended enrollment in ongoing trials or terminated these trials. The Covid-19 Dashboard on the Pharma Intelligence Center dynamically tracks these disrupted trials from the Clinical Trials Database, along with the list of companies that are the sponsor, collaborator, or contract research organization (CRO).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

GlobalData found that the majority of clinical trials, at 67.3%, were disrupted due to the suspension of enrollment, as shown in Figure 1. The delayed initiation of planned trials follows at 18.4%, then, finally, 14.4% of trials are currently being impacted due to slow enrollment. Within the 14.4% of trials affected by slow enrollment, 20.7% of these are specifically due to the availability of sites and investigators. Many hospitals that serve as trial sites are being inundated with Covid-19 patients and are no longer available. For that same reason, many investigators may be repurposed to Covid-19 drug discovery trials or treating COVID-19 patients, or activation of sites for non-COVID-19 trials are being deprioritised. There is also a high risk to subjecs in a clinical trial who have a serious chronic or acute condition that affects their immune system, giving them a greater chance of contracting Covid-19.

There are currently 322 companies that are the sponsor, collaborator, or CRO that have reported specific disrupted clinical trials in the public domain, and 179 of these are private or public companies. Just over 50% of these 179 companies are located in the US, followed by the UK at 10.6%, France at 5%, Switzerland at 5%, and Canada at 3.9%. The US is currently at the height of the Covid-19 pandemic, while many European countries experienced high incidence and mortality rates slightly earlier. Boehringer Ingelheim has the highest number of trials that have been specifically reported as disrupted in the public domain by a private or public company, but many other large pharma and biotech such as Pfizer, Eli Lilly, and Bristol-Myers Squibb have announced trial delays.

The majority of disrupted clinical trials are in Phase II, at 44.8%, followed by Phase I with 26.1%, Phase III with 21.7%, and Phase IV with 7.4%. Of these trials, 12% are specifically Pivotal/Registrational, giving an indication that there will be an impact on regulatory approvals in the future. The therapeutic area with the highest number of disrupted clinical trials is Oncology with 33.3%, followed by Central Nervous System at 16.1%, Infectious Disease at 9.3%, Gastrointestinal at 9.1%, and Respiratory at 7.7%. This follows the trend of all clinical trials in general, where number one and two are Oncology and CNS; however, Gastrointestinal usually falls outside the top five at number six and Respiratory currently stands at number eight. This may imply that trials of Respiratory indications outside of Covid-19 trials are more impacted than others due to the high risk of Covid-19.

The FDA has issued guidance for industry, investigators, and institutional review boards conducting clinical trials during the Covid-19 pandemic. Methods that could help keep the research going include virtual visits, phone interviews, self administration, and remote monitoring. These suggestions could help trials that are being met with subject quarantine and travel limitations, clinical site closures, and interrupted supply chains. However, the upward trend for clinical trial delays is expected to continue moving forward, along with a possible shift toward virtual trials.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena